NEW YORK – Swedish sample collection company Capitainer announced on Thursday that it has raised €6.7 million ($7.2 million) in a Series A financing round.
The round was led by We Venture Capital, the corporate investment arm of Werfen, and included Sciety and Sciety Venture Partners.
The funding will be used to drive Capitainer's expansion efforts, including scaling up production capacity, solidifying sales of its products in the EU and US, and initiating key collaborations, Capitainer said in a statement. The investment is the first scale-up round after years of product development, it noted.
The firm's self-sampling technology allows patients to use a card to collect blood samples that can be sent through standard mail without needing special packaging or refrigeration.
The company is scaling up by building an agent and distribution network in Europe, along with sales channels in the US.
"This investment enables us to focus our sales and marketing efforts in [the] EU and in [the] US," Capitainer CEO Christopher Aulin said in a statement. "The timing is perfect as we are now expanding sales due to the progress we have had in 2023 in diabetes monitoring, self-sampling of kidney transplanted patients, and solutions for drugs of abuse and heavy metal screening."
Last year, the company raised $5.7 million in a round led by Sciety.